Indonesia Allergy Therapeutics Market Analysis

Indonesia Allergy Therapeutics Market Executive Summary

Indonesia Allergy Therapeutics Market was valued at $139 Mn in 2022 and is estimated to reach $229 Mn in 2030, exhibiting a CAGR of 6.4% during the forecast period.

Environmental substances known as allergens occasionally trigger an immunological reaction called allergy. Common allergens include dust mites, pollen, mildew, and certain foods, including milk, eggs, soy, and almonds. From minor symptoms like a runny nose and itchy eyes to more dangerous ones like anaphylaxis, which can result in unconsciousness and breathing difficulties, allergy reactions can take many different forms. Immunotherapy, avoiding allergens, and prescription drugs such as nasal corticosteroids and antihistamines are a few possible treatment choices.

In Indonesia, allergic diseases are a significant public health issue. About 15-20% of the population suffers from allergic rhinitis, with urban rates being greater than those in rural areas. Given that some school-aged populations have prevalence rates as high as 30%, children in particular bear a heavy burden. Estimates of the prevalence of asthma among Indonesian children range from 5 to 10% across the country, with higher rates found in metropolitan regions. Atopic dermatitis affects 5–10% of children and adolescents, which is consistent with an increasing global trend in atopic dermatitis prevalence. With an estimated prevalence of 1–5%, food allergies are less common in Indonesia than in Western nations, however, peanut allergies are particularly noticeable, with rates as high as 8% in children.

A well-known player in the Indonesian pharmaceutical market, PT Kalbe Farma, has announced a strategic partnership with CytoDyn Inc. to handle the local production of Xywav (acylinezolide), a monoclonal antibody intended to treat chronic spontaneous urticaria (CSU). This partnership is a significant step in improving the accessibility of cutting-edge allergy treatments in Indonesia and furthering the nation's endeavours to increase access to innovative drugs.

Market Dynamics

Market Growth Drivers

Prevalence of Allergies: The rising incidence of respiratory allergies and other allergic illnesses, such as hay fever, is creating a need for effective allergy therapy drugs. Urbanization, changes in lifestyle, and environmental factors may all contribute to an increase in the prevalence of allergies.

Rapid Urbanization and Environmental Changes: Allergies have become more common as a result of increased urbanization and environmental changes, such as pollution and increased exposure to new allergens. The possibility of an increase in allergic reactions is driving the market for allergy medications, particularly as more people move into cities.

Advancements in Allergen Immunotherapy (AIT): Sublingual immunotherapy (SLIT) patches and pills are examples of innovative replacements that have been developed, and they may provide longer-lasting relief with fewer side effects. This creates new business opportunities for these cutting-edge treatments.

Market Restraints

High Cost of Treatment: Some people may find allergy treatment to be expensive due to its high cost, particularly when it comes to AIT techniques like immunotherapy injections and SLIT tablets. This could limit business penetration and accessibility. Many of the most effective allergy medications currently available, such as biologics and sublingual immunotherapy, are unaffordable for a sizable section of the population due to their high cost. Patients may not receive the best care possible as a result of the pricing barrier since fewer medications will be approved by the market.

Cultural and Behavioural Factors: Some communities preference for conventional drugs or home remedies over modern therapies may hinder market penetration. Reduced community awareness may make it more difficult to recognize and understand allergy symptoms, which could delay diagnosis and treatment. Using non-pharmaceutical techniques, such as air filters, to reduce allergens and/or eliminate allergy symptoms is becoming more popular despite these disadvantages.

Long-Term Treatment Commitment: Allergen immunotherapies sometimes require a long-term commitment, ranging from months to years, in order to achieve the optimum benefits. This may be challenging for people who struggle to follow treatment programs or who might not see relief right away.

Healthcare Policies and Regulatory Landscape

The national regulatory body, the Indonesian Food and Drug Authority, or Badan Pengawas Obat dan Makanan (BPOM), is in charge of assessing and authorizing marketing authorizations for pharmaceuticals, including allergy treatments, in order to guarantee their efficacy, safety, and quality. In close partnership with BPOM, the Ministry of Health develops and administers national health policies, including rules pertaining to drug safety and accessibility. The Indonesian Medical Council (IDI) establishes guidelines with a focus on ethical and professional behaviour for medical professionals, including those who prescribe medications for allergy therapy. Furthermore, the Social Security Administrative Bodies (BPJS) have a significant impact on how healthcare services are reimbursed, which may have an effect on how easily and affordably allergy drugs are available.

Competitive Landscape

Key Players

• Sanofi
• Novartis
• Boehringer Ingelheim
• GlaxoSmithKline (GSK)
• AstraZeneca
• Abbott Laboratories
• Bayer
• PT Kalbe Farma
• PT Pharos Indonesia
• PT Sanbe Farma